Tandem Diabetes Care (TNDM) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Tandem Diabetes Care (TNDM) is Neutral.

The composite score behind that read is +0.01, weighing +0.22 of bullish evidence against -0.34 bearish.

Tandem Diabetes Care last closed at $16.11, +2.74% on the session.

Against the IVW growth benchmark the position is +1.94% over the forecast window.

The read is built from 15 underlying insights — 6 bullish and 9 bearish.

Agreement across those insights is 60%.

3 graded predictions for TNDM so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Tandem Diabetes Care in the 19th percentile on return on equity, where 100 is best.

Tandem Diabetes Care is classified under Health Care / Health Care Equipment & Supplies, with a market capitalisation of $1.09B.

StockMap tracks Tandem Diabetes Care as the 57th largest of the 140 companies it covers in the Health Care Equipment & Supplies industry, part of the Health Care sector.

Across that group the current two-week reads are 122 Neutral, 16 Moderate Underperform and 2 Moderate Outperform.

On that composite Tandem Diabetes Care ranks 44th of 140 in the group, against a group median of -0.03.